Immune booster after standard therapy may stall nasopharyngeal cancer
NCT ID NCT04910347
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether the immunotherapy drug nivolumab can improve outcomes for people with locally advanced nasopharyngeal carcinoma who still have signs of cancer after standard chemoradiotherapy. About 57 adults aged 19 and older will receive nivolumab infusions every 3 weeks for up to a year. The main goal is to see how many remain cancer-free after 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nivolumab (a drug that helps the immune system fight cancer)
- What this could lead to
- If successful, this could show that adding nivolumab after standard treatment helps keep advanced nasopharyngeal cancer from returning for longer.
- What could go wrong
- This is a small, early-phase trial with only 57 people, so results may not apply to everyone. Nivolumab can cause immune-related side effects like inflammation in the lungs, gut, or skin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.